0
Researchers report that pairing a newly developed fibrin gel with CAR-T immunotherapy that was delivered to post-surgical mouse brains with glioblastoma improved the immunotherapy’s effectiveness. The gel aided CAR-T cell distribution in the brain by acclimating the T cells to the post-surgical wound environment while also stopping the tumor from recurring.